Mounjaro® for Weight Loss
(Tirzepatide) — Buy Online
Up to 22% body weight reduction — highest of any approved GLP-1 class
Medically reviewed by Dr. Jane Rote, MD,
Board-Certified Endocrinologist — Updated March 2026
Once-weekly dual GIP/GLP-1 receptor agonist proven to reduce body weight by up to 22% in phase 3 clinical trials — the highest of any approved weight loss medication class.
"Mounjaro stopped the cravings within two weeks. I started on 2.5mg and the Vitercure doctor titrated me up at exactly the right pace. 52 pounds in 7 months. I genuinely feel like a different person."
M
Marcus J.
Georgia · Mounjaro 10mg · Verified Buyer
A1C dropped 1.8 — down 31 lbs
"The Vitercure clinician reviewed my full history before prescribing — they caught that I was on a medication that could interact. I switched from Ozempic to Mounjaro and the results are in a completely different league."
J
James M.
Texas · Mounjaro 7.5mg · Verified Buyer
44 lbs — dream body achieved
"I switched to Mounjaro after plateau-ing on Wegovy. The dosage chart from my Vitercure clinician was exactly what I needed to understand the titration. 44 pounds gone. This is the medication I wish I had started with."
E
Emily R.
California · Mounjaro 12.5mg · Verified Buyer
4.9 out of 5 based on 4,102+ reviews on
Trustpilot
About Mounjaro® (Tirzepatide) for Weight Loss
Mounjaro (tirzepatide) is a once-weekly injectable medication that is both FDA-approved for Type 2 diabetes and widely prescribed for clinically supervised weight management. As the first dual GIP/GLP-1 receptor agonist ever approved, Mounjaro activates two separate incretin pathways simultaneously — an approach that delivered an average 22% body weight reduction in the SURMOUNT-1 phase 3 trial, making it the most effective GLP-1 class medication for weight loss currently available. For adults struggling with obesity or overweight with a qualifying condition, Mounjaro represents a clinically significant step change beyond single GLP-1 therapies like semaglutide. Vitercure's board-certified clinicians prescribe Mounjaro as part of a personalised, medically supervised weight loss program that includes ongoing titration management, clinical follow-up, and cold-chain pharmacy fulfillment.
How Mounjaro works — mechanism of action
Enhanced insulin release triggered only when blood sugar is elevated — reducing hypoglycemia risk
Dual incretin activation (GIP + GLP-1 pathways) for superior metabolic impact vs. single GLP-1 therapies
Reduced liver glucose output to stabilise fasting blood sugar levels
Slowed gastric emptying — helping patients feel fuller for significantly longer after meals
Central appetite regulation that reduces food cravings and total caloric intake over time
Mounjaro weight loss results — clinical trial data
Mounjaro (tirzepatide) achieved the highest average weight loss outcomes of any GLP-1 class medication in phase 3 clinical trials. The SURMOUNT-1 trial (New England Journal of Medicine, 2022) enrolled adults with obesity or overweight and at least one weight-related condition — and produced the following dose-dependent results over 72 weeks.
Dose
Avg. body weight reduction
Avg. weight lost (200 lb baseline)
% patients achieving 20%+ loss
5mg
14.9%
~30 lbs
25.2%
10mg
19.5%
~39 lbs
41.4%
15mg (max)
22.5%
~45 lbs
48.9%
Source: SURMOUNT-1 Phase 3 RCT — Jastreboff et al., NEJM 2022. Baseline ~230 lb. Results with lifestyle intervention. Individual outcomes vary significantly based on dose, adherence, and personal metabolic factors.
How Mounjaro compares to Wegovy and Ozempic for weight loss
Clinical trial data consistently shows tirzepatide (Mounjaro) achieves greater average weight loss than semaglutide (Ozempic/Wegovy) at standard doses. The SURMOUNT-5 head-to-head trial (2024) showed tirzepatide produced approximately 47% more weight loss than semaglutide 2.4mg over 72 weeks. A Vitercure clinician will recommend the most appropriate option for your clinical situation.
Mounjaro vs. Ozempic vs. Wegovy — weight loss comparison
All three medications belong to the GLP-1 receptor agonist class, but they differ in active ingredient, mechanism, FDA indication, and average weight loss outcomes. Use this table to understand the differences — then speak with a Vitercure clinician who will determine what is clinically appropriate for you.
Feature
Mounjaro® (Tirzepatide)
Wegovy® (Semaglutide 2.4mg)
Ozempic® (Semaglutide)
Active ingredient
Tirzepatide
Semaglutide
Semaglutide
Mechanism
Dual GIP + GLP-1
GLP-1 only
GLP-1 only
FDA approval
Type 2 diabetes (Zepbound for obesity)
Chronic weight management
Type 2 diabetes
Avg. weight loss (max dose)
Up to 22%
Up to 15%
Up to 12–15%
Dosing frequency
Once weekly
Once weekly
Once weekly
Starting price at Vitercure
From $449/month
From $499/month
From $399/month
Trial data from SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide 2.4mg). Prices are starting example prices — your actual quote depends on dose and clinical factors. Always consult a licensed clinician before making medication decisions.
Frequency: Inject once weekly on the same day each week.
Sites: Abdomen, thigh, or upper arm. Rotate sites to reduce irritation.
Timing: Any time of day, with or without food.
Temperature: Store in the refrigerator at 36°F–46°F (2°C–8°C). Do not freeze. Can be stored at room temperature up to 77°F for up to 21 days if needed.
Mounjaro dose titration schedule for weight loss
Week
Dose
Purpose
Weeks 1–4
2.5mg
Initiation dose to allow your body to adjust. Lower gastrointestinal side effect risk.
Weeks 5–8
5mg
First maintenance dose. Significant appetite suppression begins here for most patients.
Weeks 9–12
7.5mg
Further titration based on tolerability and weight loss response.
Weeks 13–16
10mg
Ongoing titration. Average 19.5% weight loss achieved in trials at this dose.
Weeks 17–20
12.5mg
Higher-dose option for patients who tolerate lower doses and require additional weight loss.
Week 21+
15mg
Maximum maintenance dose. Average 22.5% body weight reduction in phase 3 trials.
Your Vitercure clinician personalises your titration schedule based on your weight loss response, tolerability, other medications, and overall health history.
Important safety information
This is not complete safety information for Mounjaro. Always review the full Prescribing Information and Medication Guide and speak with a licensed clinician before starting or changing any medication.
Contraindications
Do not use Mounjaro if you have a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious hypersensitivity reaction to tirzepatide or any ingredient in Mounjaro.
Thyroid monitoring
Contact your healthcare professional promptly if you notice a neck lump, hoarseness, difficulty swallowing, or shortness of breath — these may be signs of thyroid-related issues that need urgent evaluation. Your Vitercure clinician will advise on monitoring.
Refrigerate 36°F–46°F (2°C–8°C). Do not freeze. Room temperature up to 77°F for 21 days.
FDA approval
2022 for Type 2 diabetes (Mounjaro). Tirzepatide also approved as Zepbound for chronic weight management in adults with obesity or overweight with a qualifying condition.
Manufacturer
Eli Lilly and Company
Mounjaro side effects
Side effects are most common when starting Mounjaro or increasing the dose. Most gastrointestinal symptoms reduce significantly once the body has adjusted — usually within the first 4–8 weeks at each dose level.
Gastrointestinal symptoms
Nausea, vomiting, diarrhoea, constipation, reduced appetite, and stomach discomfort are the most commonly reported effects — especially during dose titration. Symptoms typically lessen as your body adjusts over several weeks.
Injection site reactions
Mild redness, swelling, or sensitivity at the injection site can occur. Rotating injection locations each week and following proper injection technique significantly reduces the risk of irritation.
Mounjaro weight loss — frequently asked questions
The SURMOUNT-1 phase 3 clinical trial showed average body weight reductions of 14.9–22.5% over 72 weeks depending on dose (5mg, 10mg, 15mg). At the 15mg maintenance dose, roughly 1 in 3 patients achieved a 25%+ weight reduction. Real-world outcomes vary based on dose adherence, lifestyle changes, and individual metabolic factors — a Vitercure clinician will set personalised expectations for your situation.
Many patients without diabetes use Mounjaro under medical supervision for weight management. The FDA has approved the same active ingredient (tirzepatide) under the brand name Zepbound specifically for chronic weight management in adults with obesity or with overweight and a qualifying weight-related condition. Your Vitercure clinician will determine which is most appropriate for your profile.
Ozempic and Wegovy contain semaglutide and act on a single GLP-1 receptor. Mounjaro contains tirzepatide, which activates both the GLP-1 and GIP receptors simultaneously. Head-to-head and phase 3 trial data consistently show greater average weight loss with tirzepatide than with semaglutide. Your clinician will recommend the medication that is the best clinical fit for your weight, health history, and goals.
Most patients notice appetite changes and reduced food cravings within 1–3 weeks of starting Mounjaro. Visible weight loss typically builds progressively as the dose is titrated upward over the first 4–5 months. The greatest weight loss is usually observed at or after reaching the maintenance dose (5mg, 10mg, or 15mg) with consistent lifestyle changes.
If you miss a dose, take it within 4 days (96 hours) of the missed date. If more than 4 days have passed, skip the missed dose and resume on your next regularly scheduled day. Never double your dose. If you have questions about a missed dose, contact your Vitercure clinician through your secure dashboard.
Start your Mounjaro weight loss journey with a licensed clinician
Join 8,400+ Vitercure patients who reached their weight loss goals. Complete a 10-minute health intake today and a board-certified clinician will review your case within 24 hours.
